4 Imperatives For Updating Our Clinical Quality Systems Approach For 2022 Pharma

July 29, 2021
By Penelope Przekop
Clinical
Quality Systems
Quality Assurance
Risk Management

The clinical quality management systems approach developed 20 years ago is not sustainable in the today's industry because we've seen dramatic industry changes in outsourcing, remote monitoring, the use of electronic systems in clinical research, and more. But how do we update our approach for 2022 pharma? This article examines 4 imperatives, including how to accomplish them.

About the Author

Penelope Przekop, CEO

MSQA, RQAP-GCP

Penelope Przekop is a is a biopharmaceutical quality assurance and corporate compliance executive consultant with global R&D and commercial PV expertise. During the early 2000s, she developed and oversaw the first global PV quality and compliance departments established for Wyeth as well as Johson & Johnson. Her work includes qualification and oversight of numerous PV vendors covering all aspects of clinical safety and post-marketed PV. Penelope has facilitated numerous PV regulatory inspections. She frequently leads and conducts PV mock inspections and provides in-depth PV training.

Related Content

Read more from PDC’s teams of experts.

3 Surefire Approaches To SOP Harmonization

Standard operating procedures (SOPs) have become the documentation backbone of our industry and, yes, at times, a major pain in the neck. Those of us who were around during the 80s may be able to recall fuzzy memories of SOPs being a thing . Fast forward to 2019, past the birth of ICH, the evolution of outsourcing, the techno explosion and the FDA’s 21 CFR Part 11, the EU obsession with quality systems, and the more recent rise of the big vendor. Today, we’re buried in mountains of SOPs.

Learn more
3 Surefire Approaches To SOP Harmonization

Standard operating procedures (SOPs) have become the documentation backbone of our industry and, yes, at times, a major pain in the neck. Those of us who were around during the 80s may be able to recall fuzzy memories of SOPs being a thing . Fast forward to 2019, past the birth of ICH, the evolution of outsourcing, the techno explosion and the FDA’s 21 CFR Part 11, the EU obsession with quality systems, and the more recent rise of the big vendor. Today, we’re buried in mountains of SOPs.

Learn more
How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

Amid all this financial and operational strategizing, a huge puzzle piece is often left to the side: compliance.

Learn more
How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

Amid all this financial and operational strategizing, a huge puzzle piece is often left to the side: compliance.

Learn more
How To Improve FDA Inspection Readiness & Outcomes By Mining Publicly Available Data

Now that we have years of real-world regulatory outcomes data available, why are we ignoring their power to serve as a corrective lens for our interpretations of the law?

Learn more
How To Improve FDA Inspection Readiness & Outcomes By Mining Publicly Available Data

Now that we have years of real-world regulatory outcomes data available, why are we ignoring their power to serve as a corrective lens for our interpretations of the law?

Learn more
3 Reasons Why Sponsors Must Review Monitoring Reports

Despite recent progress in executing and documenting oversight, sponsor oversight remains a challenge, especially with monitoring reports. Penelope Przekop detail three reasons why they must remain top of mind.

Learn more
3 Reasons Why Sponsors Must Review Monitoring Reports

Despite recent progress in executing and documenting oversight, sponsor oversight remains a challenge, especially with monitoring reports. Penelope Przekop detail three reasons why they must remain top of mind.

Learn more

How can we help you?

Reach out to schedule a consultation.

Contact PDC